Identification of two novel mutations in the SLC45A2 gene in a Hungarian pedigree affected by unusual OCA type 4

Lola Tóth 1, Beáta Fábos 2, Katalin Farkas 3, Adrienn Sulák 1, Kornélia Tripolszki 1, Márta Széll 1,3 and Nikoletta Nagy 1,3,4*

Abstract

Background: Oculocutaneous albinism (OCA) is a clinically and genetically heterogenic group of pigmentation abnormalities. OCA type IV (OCA4, OMIM 606574) develops due to homozygous or compound heterozygous mutations in the solute carrier family 45, member 2 (SLC45A2) gene. This gene encodes a membrane-associated transport protein, which regulates tyrosinase activity and, thus, melanin content by changing melanosomal pH and disrupting the incorporation of copper into tyrosinase.

Methods: Here we report two Hungarian siblings affected by an unusual OCA4 phenotype. After genomic DNA was isolated from peripheral blood of the patients, the coding regions of the SLC45A2 gene were sequenced. In silico tools were applied to identify the functional impact of the newly detected mutations.

Results: Direct sequencing of the SLC45A2 gene revealed two novel, heterozygous mutations, one missense (c.1226G > A, p.Gly409Asp) and one nonsense (c.1459C > T, p.Gln437*), which were present in both patients, suggesting the mutations were compound heterozygous. In silico tools suggest that these variations are disease causing mutations.

Conclusions: The newly identified mutations may affect the transmembrane domains of the protein, and could impair transport function, resulting in decreases in both melanosomal pH and tyrosinase activity. Our study provides expands on the mutation spectrum of the SLC45A2 gene and the genetic background of OCA4.

Keywords: Oculocutaneous albinism type 4, Unusual phenotype, SLC45A2 gene, Compound heterozygous state, Novel mutations
To date, 78 of the mutations identified in the SLC45A2 gene are related to OCA4 [7]. In this study, we report a Hungarian family with two members affected by OCA4. Our genetic investigation identified that these members carried two novel heterozygous mutations in a compound heterozygous state, expanding the mutational spectrum of OCA4.

**Methods**

**Patients**

A Hungarian family with two affected siblings was investigated (Fig. 1). The affected individuals were 30 (Patient II/1) and 27 years (Patient II/2) old at the time of investigation. Both exhibited pale skin, complete absence of hair pigment, pink nevi and blue eyes with nystagmus. This complete absence of pigmentation is unusual for OCA4. Patient II/1 has been suffering from Crohn’s disease for 9 years and hypothyreosis for 4 years. Patient II/2 was not aware of any known concomitant diseases. The parents (I/1 and I/2) of the affected siblings are clinically unaffected by OCA4. The investigated patients declined publication of their clinical pictures.

**Genetic investigation**

Blood was taken from the affected patients as well as from unrelated, healthy Hungarian individuals without pigmentation abnormality (n = 30), and genomic DNA was isolated using a BioRobot EZ1 DSP Workstation (QIAGEN; Godollo, Hungary). The entire coding region of the SLC45A2 gene and the flanking introns were amplified and sequenced (primer sequences used were taken from the UCSC Genome Browser www.genome.ucsc.edu). The investigation was approved by the Internal Review Board of the University of Szeged. Written informed consent was obtained from the patient and the study was conducted according to the Principles of the Declaration of Helsinki. After identifying the causative mutations in the patients, further genetic screening of the parents was declined.

**Pathogenicity predictions for missense variants**

In silico tools were applied to identify the functional role of the newly found variants. Here we used SIFT (Sorting In tolerant from Tolerant, http://sift.jcvi.org/), PolyPhen2 (Polymorphism Phenotyping, http://genetics.bwh.harvard.edu/pph2), Mutation Taster (http://www.mutationtaster.org/), PredictSNP (http://loschmidt.chemi.muni.cz/predictsnp/) PROVEAN (Protein Variation Effect Analyzer, http://provean.jcvi.org/index.php) and PANTHER (Protein ANalysis THrough Evolutionary Relationships, http://www.pantherdb.org/) tools.

**Results**

Direct sequencing of the coding regions and the flanking introns of the SLC45A2 gene revealed two heterozygous mutations, one missense mutation (c.1226G > A, p.Gly409Asp) in the sixth exon (Fig. 2a) and one nonsense mutation (c.1459C > T, p.Gln437*) in the seventh exon (Fig. 2b). Both patients carried both mutations, suggesting a compound heterozygous state. Unrelated healthy controls carried the wild type sequence. To decide, whether the detected missense mutation is pathogenic, we use in silico analysis tools (SIFT, PolyPhen2, Mutation Taster, PredictSNP, PROVEAN and PANTHER). All prediction tools suggested that the p.Gly409Asp mutation is deleterious. The nonsense mutation was deemed to be pathogenic. It causes the development of a premature termination codon at 487 amino acid position thereby the MATP protein truncated and it may lead to its dysfunction.

**Discussion**

Both mutations are situated in transmembrane domains of the MATP protein (Uniprot: Q9UMX9): the p.Gly409Asp missense mutation is located within the ninth domain and the p.Gln437* nonsense mutation within the tenth (Fig. 2c). The locations of the mutations suggest that they impair the transport function of the MATP protein. MATP dysfunction might cause an acidic melanosomal lumen, leading to improper incorporation of copper into tyrosinase. The reduced tyrosinase activity could, in turn, lead to the development of the OCA phenotype [6]. The p.Gly409Asp missense mutation affects an evolutionary conserved region of the MATP protein (Fig. 2d), further emphasizing the
putative pathogenic role of this mutation in the development of the observed pigmentation abnormalities of the affected patients.

Mutations of the \textit{SLC45A2} gene have been reported to cause complete or partial loss of pigmentation, thus contributing to the development of several different OCA phenotypes. However, a genotype–phenotype correlation based on the \textit{SLC45A2} mutations and the patients’ clinical symptoms has not yet been established for OCA4 [8]. Mutations of the \textit{SLC45A2} gene are typically associated with partial loss of pigmentation, referred to as the “brown OCA” phenotype [7]. The two siblings reported here exhibited an unusual OCA4 phenotype, as they developed the complete absence of pigmentation. This phenotype is more common in type 1 OCA, which is caused by mutations in the tyrosinase (\textit{TYR}) gene. To rule out the influence of other putative genetic-modifier variants responsible for the unusual phenotype, the \textit{TYR} and \textit{OCA2} genes were also performed. Common polymorphisms of \textit{TYR} gene were detected, neither pathogenic nor non-pathogenic variants of the \textit{OCA2} gene were identified. Patient II/1 carried the p.Ser192Tyr variant homozygously and the p.Arg402Gln variant heterozygously. Heterozygous p.Ser192Tyr polymorphism was identified in Patient II/2. These two common variants of \textit{TYR} gene occur at high frequency (p.Ser192Tyr: Global MAF: 0.1234, Caucasian MAF: 0.3718; p.Arg402Gln: Global MAF: 0.0813, Caucasian MAF: 0.2525) but were not directly related to pigmentation phenotypes in normal Caucasians [9]. However, functional studies reported that 192Tyr and 402Gln alleles have reduced TYR enzyme activity. Heterozygous p.Ser192Tyr and p.Arg402Gln variants caused significant reduction in TYR expression, and a consistent decrease in TYR protein levels was observed in homozygous p.Ser192Tyr cells [9].

Since one of our investigated OCA4 patients (II/1) is also affected by Chron’s disease, it is possible that the mutations of the \textit{SLC45A2} gene could be susceptibility factors for the development of Chron’s disease. This hypothesis is further supported by the literature, since a previous study reporting a sister and a brother affected by congenital neutropenia and oculocutaneous albinism identified a nonsense mutation in the G6PC3 gene (c.829C > T, p.Gln277*) responsible for the development of congenital neutropenia and frameshift mutation in the \textit{SLC45A2} gene (c.986delC, p.T329Rfs*68), which could explain the OCA phenotype [10]. In this previous study, the investigated brother is also affected by Chron’s disease, suggesting a putative association between the mutations of the \textit{SLC45A2} gene and Chron’s disease [10].

OCA has been considered for many years as a group of monogenic rare diseases without cure. Accumulating knowledge regarding the underlying mechanism of the OCA4 might alter this viewpoint: it has been recently
demonstrated in MNT-1 cell lysates that exogenously applied copper recovers reduced tyrosinase activity resulting from \( \text{SLC45A2} \) knockdown [6].

**Conclusions**

In conclusion, we report two novel heterozygous mutations, one missense and one nonsense, of the \( \text{SLC45A2} \) gene in two Hungarian sisters affected by OCA4. The prediction analysis and the location of the mutations as well as the evolutionary conservation of the missense mutation suggest a pathogenic role in the development of OCA4. Our report, which further contributes to the mutation spectrum of the \( \text{SLC45A2} \) gene as well as to the spectrum of the observed unusual clinical symptoms, will hopefully contribute to future studies characterizing genotype-phenotype correlations in OCA4. This study provides expands to the genetic background of OCA4 and might serve as a basis for future studies aiming to develop novel therapeutic approaches for OCA patients.

**Abbreviations**

\( \text{G6PC3} \): Glucose 6 phosphatase, catalytic, 3 gene; \( \text{MATP} \): Membrane-associated transport protein; \( \text{MNT-1} \): Human melanoma cell line; \( \text{OCA} \): Oculocutaneous albinism; \( \text{OCA2} \): Oculocutaneous albinism II gene; \( \text{OCA4} \): Oculocutaneous albinism type IV; \( \text{RXGRR} \): A conserved amino acid motif; \( \text{SCN4} \): Severe congenital neutropenia type 4; \( \text{SCN4A} \): Sodium channel, voltage gated, type IV gene; \( \text{SLC45A2} \): Solute carrier family 45, member 2 gene; \( \text{TYR} \): Tyrosinase gene.

**Acknowledgements**

We would like to thank all the participants for participating in this investigation.

**Funding**

This study was supported by the Hungarian TÁMOP-4.2.2.A-11/1-KONV-2012-0035 grant, TÁMOP-4.2.2.A-11-1-2012-0001 grant, TÁMOP-4.2.2.A-11-1-2012-0035 grant and GINOP-2.3.2-15-2016-00039.

**Availability of data and materials**

All of the data are included in the manuscript.

**Authors’ contributions**

LT carried out the mutation analysis and the first draft of the manuscript. BF, AS and KT participated in the mutation analysis. MS and NN were mentors who designed and guided the research study. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

All the reported patients gave their informed consent to the publication.

**Ethics approval and consent to participate**

The investigation was approved by the Internal Review Board of the University of Szeged. Written informed consent was obtained from the patients and unrelated healthy individuals. The study was conducted according to the Principles of the Declaration of Helsinki.

**Author details**

1. Department of Medical Genetics, University of Szeged, 6 Somogyi Bela Street, 6720 Szeged, Hungary. 2. Mór Kaposi Teaching Hospital of the Somogy County, Kaposvár, Hungary. 3. MTA-SZTE Dermatological Research Group, University of Szeged, Szeged, Hungary. 4. Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.

**Received:** 26 November 2015 **Accepted:** 1 March 2017

**Published online:** 15 March 2017

**References**

1. Martínez-García M, Montoliu L. Albinism in Europe. J Dermatol. 2013;40:319–24.
2. Ghodsinejad Kalahroudi V, Kamalideghhan B, Arasteh Kani A, Ayani O, Tondar M, Ahmadipour F, et al. Two novel tyrosinase (\( \text{TYR} \)) gene mutations with pathogenic impact on oculocutaneous albinism type 1 (OCA1). PLoS One. 2014;9:e106656.
3. Newton JM, Cohen-Barak O, Hagiwara N, Gardner JM, Davisson MT, King RA, Brilliant MH. Mutations in the human orthologue of the mouse underwhite gene (uw) underlie a new form of oculocutaneous albinism, OCA4. Am J Hum Genet. 2001;69:981–8.
4. Fukamachi S, Shimada A, Shima A. Mutations in the gene encoding B, a novel transporter protein, reduce melanin content in medaka. Nat Genet. 2001;28:381–5.
5. Meyer H, Vitavska O, Weczorek H. Identification of an animal sucrose transporter. J Cell Sci. 2011;124:1984–91.
6. Bin BH, Bhin J, Yang SH, Shin M, Nam YJ, Choi DH, et al. Membrane-Associated Transporter Protein (\( \text{MATP} \)) regulates melanosomal pH and influences tyrosinase activity. PLoS One. 2015;10:e0129273.
7. Kamaraj B, Purohit R. Mutational analysis of oculocutaneous albinism: a compact review. Biomed Res Int. 2014;2014:905472.
8. Simeonov DR, Wang X, Wang C, Sereev Y, Dolinska M, Bover M, et al. DNA variations in oculocutaneous albinism: an updated mutation list and current outstanding issues in molecular diagnostics. Hum Mutat. 2013;34:827–35.
9. Jagirdar K, Smit DJ, Ainger SA, Lee KJ, Brown DL, Chapman B, et al. Molecular analysis of common polymorphisms within the human Tyrosinase locus and genetic association with pigmentation traits. Pigment Cell Melanoma Res. 2014;27:552–64.
10. Fernandez BA, Green JS, Busrey F, Barrett B, MacMillan A, McColl S, et al. Adult siblings with homozygous G6PC3 mutations expand our understanding of the severe congenital neutropenia type 4 (SCN4) phenotype. BMC Med Genet. 2012;13:1111.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.